All Content

Extending the duration of androgen suppression in men with intermediate-risk prostate cancer prior to radiotherapy led to more adverse events and did not improve outcomes.

An analysis of a large number of women suggested that those who use bisphosphonates, a bone medication used to treat osteoporosis and other bone loss diseases, have a reduced risk of endometrial cancer.

According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.

Addition of PI3 Kinase Inhibitor in ER-Positive Breast Cancer Raises Questions

This slide show features some of the top highlights from the 2014 San Antonio Breast Cancer Symposium, including ovarian suppression in ER-positive breast tumors, tamoxifen for disease prevention, and immunotherapies for triple-negative breast cancer.

Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.

Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.

The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Risk for febrile neutropenia was high among patients with metastases from a variety of common cancers and was associated with numerous clinical and economic consequences, including increased morbidity and mortality.

Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.

A large trial showed that treatment-emergent vasomotor and/or joint symptoms do not correlate with any improvement in recurrence-free survival in postmenopausal breast cancer patients treated with aromatase inhibitors.


By clicking Accept, you agree to become a member of the UBM Medica Community.